Loss of ARID1A expression also leads to chemotherapy resistance in a variety of tumors, including lung cancer (Huang et al., 2024), ovarian cancer (Duska et al., 2023) and pancreatic cancer (Li et al., 2022). Here, ARID1A is linked to familial pancreatic carcinoma.